Finance and markets: business, quotes, gold, energy and releases.
RaQualia Pharma reported a net loss of ¥493 million for the nine months ended September 30, 2026, narrowing from a ¥568 million loss in the same period of 2025. Revenue rose to ¥2.35 billion from ¥2.31 billion, according to results prepared under Japanese accounting standards.
The company’s operating loss was ¥238 million, compared with ¥344 million a year earlier. Its pretax loss narrowed to ¥261 million from ¥426 million.
Loss per share was ¥19.08, against ¥24.29 in the corresponding period of 2025. Figures are for the group’s nine-month periods ended September 30.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!